XML 47 R28.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2023

Net service revenue by payor class as a percentage of total net service revenue for each of our operating segments as described in Note 15 – Segment Information is as follows:


	As of December 31,
	2023		2022		2021
Home Health:
Medicare	39	%	40	%	41	%
Non-Medicare - Episodic-based	8	%	8	%	8	%
Non-Medicare - Non-episodic based	15	%	13	%	12	%
Hospice:
Medicare	34	%	33	%	34	%
Non-Medicare	2	%	2	%	2	%
Personal Care (1)	1	%	3	%	3	%
High Acuity Care (2)	1	%	1	%	—	%
	100	%	100	%	100	%

(1) We divested our personal care business on March 31, 2023.

(2) We acquired Contessa Health on August 1, 2021.

Schedule of Cash Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):


	As of December 31,
	2023		2022
Cash and cash equivalents	$	126.5	$	40.5
Restricted cash	12.4		13.6
Cash, cash equivalents and restricted cash	$	138.9	$	54.1

Schedule of Estimated Useful Lives of Property and Equipment

We generally provide for depreciation over the following estimated useful service lives.


			Years
Buildings			39
Leasehold improvements			Lesser of lease term or expected useful life
Equipment and furniture			3 to 7
Vehicles			5
Computer software			2 to 7
Leased copiers			Lesser of lease term or expected useful life
Leased fleet			Lesser of lease term or expected useful life

Schedule of Property and Equipment

The following table summarizes the balances related to our property and equipment for 2023 and 2022 (amounts in millions):


	As of December 31,
	2023		2022
Buildings and leasehold improvements	$	11.0	$	9.7
Equipment and furniture	40.0		56.9
Finance leases	39.8		4.1
Computer software	43.4		46.7
	134.2		117.4
Less: Accumulated depreciation	(92.4)		(101.4)
	$	41.8	$	16.0

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of December 31, 2023		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	371.9	$	—	$	360.6	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net (loss) income attributable to Amedisys, Inc. common stockholders (amounts in thousands):


	For the Years Ended December 31,
	2023	2022	2021
Weighted average number of shares outstanding – basic	32,599	32,517	32,642
Effect of dilutive securities:
Stock options	—	39	122
Non-vested stock and stock units	—	97	208
Weighted average number of shares outstanding – diluted	32,599	32,653	32,972
Anti-dilutive securities	619	303	114